Orthocell has been named as a biotech stock to watch by Michael Frazis, founder of Frazis Capital Partners, on a recent episode the Equity Mates Investing Podcast.
Franzis mentions Orthocell’s recent capital raise, and plans for expansion into the US market, highlighting the Company’s opportunity to achieve substantial growth
Have a listen: